The bootstrapping method was used to estimate average BG and corresponding HbA1c.
2
Subgroup analyses were done in diabetic patients according to their Hba1C levels.
3
HbA1c determinations were centralized in a Diabetes Control and Complications Trial-controlled laboratory.
4
The HbA1c is a really important test that we use all the time.
5
Conclusions: This study showed that HbA1c is a good predictor of in-hospital morbidity.
1
Some SMBG time points had a stronger association with A1C than others.
2
Higher levels of A1c suggest worse blood sugar control and possibly diabetes.
3
Blood pressure and hemoglobin A1c did not differ among the four groups.
4
They were more likely to document patient height, urinalyses results, and A1C values.
5
High A1C levels mean a high risk of complications from diabetes.
1
Blood pressure and hemoglobinA1c did not differ among the four groups.
2
BP and insulin resistance, reflected by hemoglobinA1c, were among cardiovascular risk factors.
3
Lipid profile, hemoglobinA1c and systemic blood pressure were measured in all patients.
4
Blood pressure, blood levels of hemoglobinA1c, and serum lipids were also measured.
5
These so-called hemoglobinA1c levels reflect average blood sugar levels over about three months.
1
Baseline BMI predicted greater fasting glucose and HgbA1c levels at 12 months for both treatments.
Ús de glycated hemoglobin en anglès
1
Primary outcome: We evaluated mean change in blood glycatedhemoglobin levels.
2
Glycemic control was based on glycatedhemoglobin levels and fasting blood glucose test.
3
Measurements and main results: We used admission glycatedhemoglobin to estimate premorbid baseline blood glucose concentration.
4
Higher total cholesterol, glycatedhemoglobin and insulin resistance parameters are connected with lower central dopamine tone.
5
Glucose-lowering therapies were granted regulatory approval primarily from smaller studies that have demonstrated reductions in glycatedhemoglobin concentration.
6
Top five factors in RF importance ranking were: waist, glucose, uric acid, and red cell distribution width and glycatedhemoglobin.
7
Between-group differences in blood pressure and glycatedhemoglobin levels during the trial were no longer evident by the first post-trial visit.
8
No correlation was seen between pancreatic volume index in patients and diabetes duration, glucose or C-peptide levels, glycatedhemoglobin, and islet autoantibodies.
9
The average duration of diagnosed diabetes was 10.8 years and the mean glycatedhemoglobin value was 10.8%.
10
Body mass index, blood pressure, fasting blood sugar, glycatedhemoglobin, lipid profile and antioxidants were measured at baseline and at every three months interval.
11
Aims: We describe a two-step screening approach using non-invasive risk assessment and glycatedhemoglobin (HbA1c) to identify participants for a diabetes prevention trial.
12
Individuals diagnosed with TB underwent glycatedhemoglobin (HbA1c) testing at the time of anti-tuberculous treatment initiation and at three -month follow up stage.
13
There was a trend towards greater T2D and hypertension remission rate after OAGB, while fasting glucose and glycatedhemoglobin levels were significantly lower after OAGB.
14
Changes in the glycatedhemoglobin (HbA1c) level after 3 months of treatment were compared with the baseline, and exploratory analysis was performed.
15
Glycatedhemoglobin is a measure of the patient's blood sugar control for the past two to three months.